Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
NCT ID: NCT02804100
Last Updated: 2016-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2016-05-31
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed stage IIIB/IV NSCLC.
* Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q)
* Able to comply with the required protocol and followed-up procedures, and able to receive oral medications
Exclusion Criteria
* Patient had received prior chemotherapy or EGFR-TKIs treatment
* Patients who harbor Exon20 T790M mutation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wenzhou Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chunming Ding
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wenfeng Li, Ph.D
Role: STUDY_CHAIR
First Affiliated Hospital of Wenzhou Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wenzhou Medical University
Wenzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ju Luan, PhD
Role: primary
Wenfeng Li, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Yang Z, Li J, Hu Y, Chen M, Peng D, Zong D, Shang Q, Tao L, Zhao Y, Ni Y, Ye J, Xie Y, Yang L, Lin Q, Cai C, Xu N, Huang X, Dong X, Zhou Z, Yu Y, Shangguan Z, Xu Y, Ying W, Weng M, Yuan Z, Dong Z, Li J, Zheng Z, Pan J, Liu L, Ye J, Zhang Z, Li W, Zhu J, Jin S, Li Y, Ding C. Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study. Target Oncol. 2019 Dec;14(6):719-728. doi: 10.1007/s11523-019-00682-0.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4241616009G
Identifier Type: -
Identifier Source: org_study_id